Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 5/20 | 0.41 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ITGA1 | P56199 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129226 | 1.00 | TRPV4 (0.41) | TRPV4GSTO1NPSR1FABP4SMN1; SMN2 | |
| SCHEMBL4139634 | 0.94 | TRPV4 (0.39) | TRPV4GSTO1NPSR1FABP4SMN1; SMN2 | |
| SCHEMBL4129734 | 0.94 | TRPV4 (0.39) | TRPV4GSTO1FABP4GAAITGA1 | |
| SCHEMBL4142797 | 0.94 | TRPV4 (0.39) | TRPV4GSTO1NPSR1FABP4SMN1; SMN2 | |
| SCHEMBL4129723 | 0.94 | TRPV4 (0.39) | TRPV4GSTO1FABP4GAAITGA1 | |
| SCHEMBL4135071 | 0.94 | TRPV4 (0.39) | TRPV4GSTO1FABP4GAAITGA1 | |
| SCHEMBL4132199 | 0.86 | BMP1 (0.35) | TRPV4GSTO1FABP4SMN1; SMN2PKM | |
| SCHEMBL4140505 | 0.86 | BMP1 (0.35) | TRPV4GSTO1FABP4SMN1; SMN2PKM | |
| SCHEMBL4148627 | 0.86 | BMP1 (0.37) | TRPV4GSTO1FABP4SMN1; SMN2PKM | |
| SCHEMBL4148621 | 0.86 | BMP1 (0.37) | TRPV4GSTO1FABP4SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | TRPV4 1/4885GSTO1 4156/4885NPSR1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.